Institution · Renal Associates P. A.
Most cited papers from Renal Associates P. A.
What are the most cited papers from Renal Associates P. A.?
The most cited paper from Renal Associates P. A. is "Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes" (Pablo E. Pérgola, Philip Raskin, Robert Daniel Toto et al., 2011), with 886 citations. Next come "Sugar, Uric Acid, and the Etiology of Diabetes and Obesity" (764) and "IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial" (730).
Showing 50 of 60 papers. Every paper with more than 37 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes Pablo E. Pérgola, Philip Raskin, Robert Daniel Toto et al. · New England Journal of Medicine | 24 Jun 2011 | 886 |
| 2 | Sugar, Uric Acid, and the Etiology of Diabetes and Obesity Richard J. Johnson, Takahiko Nakagawa, Laura Gabriela Sánchez‐Lozada et al. · Diabetes | 17 Sep 2013 | 764 |
| 3 | IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet | May 2021 | 730 |
| 4 | Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease Stacey Ruiz, Pablo E. Pérgola, Richard A. Zager et al. · Kidney International | 16 Jan 2013 | 722 |
| 5 | European S3‐Guidelines on the systemic treatment of psoriasis vulgaris Delano Pathirana et al. · Journal of the European Academy of Dermatology and Venereology | 26 Aug 2009 | 705 |
| 6 | Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink et al. · The Lancet | 14 Apr 2019 | 633 |
| 7 | Sodium Zirconium Cyclosilicate in Hyperkalemia David Packham, Henrik Sandvad Rasmussen, Philip T. Lavin et al. · New England Journal of Medicine | 21 Nov 2014 | 505 |
| 8 | Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment Elizabeth Katherine Batchelor, Pinelopi P. Kapitsinou, Pablo E. Pérgola et al. · Journal of the American Society of Nephrology | 10 Feb 2020 | 340 |
| 9 | Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study Robert Provenzano, Anatole Besarab, Steven Charles Wright et al. · American Journal of Kidney Diseases | 2 Feb 2016 | 263 |
| 10 | Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD Glenn Matthew Chertow et al. · New England Journal of Medicine | 28 Apr 2021 | 253 |
| 11 | Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease Pablo E. Pérgola, Bruce Spinowitz, Charlotte Hartman et al. · Kidney International | 18 Sep 2016 | 237 |
| 12 | Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD Pablo E. Pérgola, Melissa Krauth, Jesse W. Huff et al. · American Journal of Nephrology | 2011 | 233 |
| 13 | A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD David B. Van Wyck, Michael Roppolo, Carlos Orlando Alfaro Martínez et al. · Kidney International | 15 Nov 2005 | 225 |
| 14 | Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia Bruce Spinowitz, Steven N. Fishbane, Pablo E. Pérgola et al. · Clinical Journal of the American Society of Nephrology | 20 May 2019 | 197 |
| 15 | Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study Steven N. Fishbane, Mohamed A. El-Shahawy, Roberto Pecoits‐Filho et al. · Journal of the American Society of Nephrology | 10 Feb 2021 | 182 |
| 16 | Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Susan C. Taylor, Helen Torok, Terry M. Jones et al. · PubMed | Jul 2003 | 172 |
| 17 | Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study Melanie P. Chin, George L. Bakris, Geoffrey A. Block et al. · American Journal of Nephrology | 2018 | 165 |
| 18 | A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5 Geoffrey A. Block, Steven N. Fishbane, Mariano Rodríguez et al. · American Journal of Kidney Diseases | 4 Nov 2014 | 152 |
| 19 | Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study Steven Fishbane, Carol A. Pollock, Mohamed El-Shahawy et al. · Journal of the American Society of Nephrology | 31 Mar 2022 | 143 |
| 20 | Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis Shuchi Anand, Maria E. Montez‐Rath, Jialin Han et al. · Journal of the American Society of Nephrology | 11 Jun 2021 | 123 |
| 21 | Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia Steven N. Fishbane, Geoffrey A. Block, Lisa Carole Loram et al. · Journal of the American Society of Nephrology | 12 Jan 2017 | 121 |
| 22 | Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study Andrea Matus González, Talia Gutman, Pamela A Lopez‐Vargas et al. · American Journal of Kidney Diseases | 31 May 2020 | 120 |
| 23 | Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis Iain C. Macdougall, Robert Provenzano, Amit Kumar Sharma et al. · New England Journal of Medicine | 23 Jan 2013 | 119 |
| 24 | Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study George L. Bakris, Pablo E. Pérgola, Belkis Delgado et al. · Hypertension | 10 May 2021 | 115 |
| 25 | Pharmacokinetic Study of Ferumoxytol: A New Iron Replacement Therapy in Normal Subjects and Hemodialysis Patients Robert Landry, Paula M. Jacobs, Robert H. Davis et al. · American Journal of Nephrology | 2005 | 108 |
| 26 | Effects of Selonsertib in Patients with Diabetic Kidney Disease Glenn Matthew Chertow, Pablo E. Pérgola, Chen Fang et al. · Journal of the American Society of Nephrology | 10 Sep 2019 | 96 |
| 27 | Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal et al. · American Journal of Nephrology | 2013 | 94 |
| 28 | The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease Neera K. Dahl, Michelle S. Bloom, Fouad T. Chebib et al. · Journal of the American Society of Nephrology | 5 Oct 2023 | 92 |
| 29 | A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY) Pablo E. Pérgola, David P. Rosenbaum, Yang� Yang et al. · Journal of the American Society of Nephrology | 28 May 2021 | 91 |
| 30 | Contrast-Induced Nephropathy Michael R. Rudnick, Stanley Goldfarb, James Alan Tumlin · Clinical Journal of the American Society of Nephrology | 12 Dec 2007 | 87 |
| 31 | Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease Pablo E. Pérgola, Steven N. Fishbane, Tomas Ganz · Advances in Chronic Kidney Disease | Jul 2019 | 86 |
| 32 | Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Pablo E. Pérgola, Matt Devalaraja, Steven Fishbane et al. · Journal of the American Society of Nephrology | 3 Dec 2020 | 85 |
| 33 | Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review Bruce Spinowitz, Roberto Pecoits‐Filho, Wolfgang C. Winkelmayer et al. · Journal of Medical Economics | 28 Feb 2019 | 83 |
| 34 | Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease Robert S. Janssen, Roberto Mangoo‐Karim, Pablo E. Pérgola et al. · Vaccine | 30 May 2013 | 82 |
| 35 | Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study Luis Miguel Ruilope, Bertram Pitt, Stefan D. Anker et al. · Nephrology Dialysis Transplantation | 20 Apr 2022 | 81 |
| 36 | Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents Volker H. Haase, Glenn Matthew Chertow, Geoffrey A. Block et al. · Nephrology Dialysis Transplantation | 9 Mar 2018 | 73 |
| 37 | Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial Michelle C. Odden, Leslie A. McClure, Boutros Peter Sawaya et al. · Hypertension | 10 Nov 2015 | 71 |
| 38 | Maternal Hypercalcemia Due to Failure of 1,25-Dihydroxyvitamin-D3Catabolism in a Patient WithCYP24A1Mutations Arti D. Shah, Edward Chiaming Hsiao, Betsy E. O’Donnell et al. · The Journal of Clinical Endocrinology & Metabolism | 22 Jun 2015 | 63 |
| 39 | Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health Allison Tong, Andrew S. Levey, Kai‐Uwe Eckardt et al. · Clinical Journal of the American Society of Nephrology | 25 Jun 2020 | 62 |
| 40 | Current Management of Hyperkalemia in Patients on Dialysis Shweta Bansal, Pablo E. Pérgola · Kidney International Reports | 25 Feb 2020 | 62 |
| 41 | Epstein–Barr virus and renal transplantation Jade Le, Christine M. Durand, Irfan A. Agha et al. · Transplantation Reviews | 29 Dec 2016 | 59 |
| 42 | SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis Shuchi Anand, Maria E. Montez-Rath, Jialin Han et al. · Annals of Internal Medicine | 14 Dec 2021 | 57 |
| 43 | Central vein stenosis in hemodialysis vascular access: clinical manifestations and contemporary management strategies Gift Chiechekam Echefu, Ifeoluwa Stowe, Abdulkareem O. Lukan et al. · Frontiers in Nephrology | 9 Nov 2023 | 56 |
| 44 | Blood Pressure After Recent Stroke: Baseline Findings From the Secondary Prevention of Small Subcortical Strokes Trial Carole L. White, Pablo E. Pérgola, Jeff M. Szychowski et al. · American Journal of Hypertension | 4 Jun 2013 | 56 |
| 45 | Pathophysiological concepts and screening of cardiovascular disease in dialysis patients Gift Chiechekam Echefu, Ifeoluwa Stowe, Semenawit Burka et al. · Frontiers in Nephrology | 29 Sep 2023 | 52 |
| 46 | Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy Jeremy D. Gale, Steven A. Gilbert, Samuel S. Blumenthal et al. · Kidney International Reports | 2 Aug 2018 | 52 |
| 47 | Smoking-Related Glomerulopathy: Expanding the Morphologic Spectrum Steven Salvatore, Megan L. Troxell, Douglas Hecox et al. · American Journal of Nephrology | 2015 | 51 |
| 48 | Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome Glenn Matthew Chertow et al. · American Journal of Nephrology | 2021 | 49 |
| 49 | Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET) Radko Komers, Debbie S. Gipson, Peter Jon Nelson et al. · Kidney International Reports | 5 Mar 2017 | 49 |
| 50 | Effects of Bardoxolone Methyl in Alport Syndrome Bradley A. Warady et al. · Clinical Journal of the American Society of Nephrology | 21 Nov 2022 | 48 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.